Raphael Landovitz, MD, MSc (Biomedical HIV Prevention) is Assistant Professor of Medicine in the Department of Medicine, Division of Infectious Diseases. Dr. Landovitz’s research focuses on pre- and post-exposure antiretroviral prophylaxis and other biomedical strategies to prevent HIV infection in methamphetamine users and other high-risk populations, and the use of novel technologies for epidemiologic assessment, HIV prevention messaging, and study recruitment.
Post Exposure Prophylaxis
HIV Treatment as Prevention
Selected Recent Publications:
Landovitz RJ, Fletcher JB, Shoptaw S, Reback CJ. Contingency Management facilitates the use of Post-Exposure Prophylaxis among Stimulant-using Men who have Sex with Men. Open Forum Infectious Diseases. 2015.
Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1: A Randomized, Controlled Equivalence Trial. Ann Intern Med. 2014 Oct 7;161(7):461-71
Beymer MR, Bolan RK, Flynn RP, Kerrone DR, Pieribone DL,Kulkarni SP, Stitt JC, Mejia E, Landovitz RJ. Uptake and repeat use of post-exposure prophylaxis in a community-based clinic in Los Angeles, California. AIDS Res Hum Retroviruses. 2014 Sep;30(9):848-55.
Landovitz RJ, Fletcher JB, Shoptaw S, Reback CJ. A Novel Combination HIV Prevention Strategy: Post-Exposure Prophylaxis with Contingency Management for Substance Abuse Treatment among Methamphetamine-using Men who have Sex with Men. AIDS Patient Care STDS. 2012 Jun;26(6):320-8.
The priority application deadline is Friday, January 10th, 2020.